SB-140 

SB-140 is a selective, covalent PLpro inhibitor with an IC₅₀ of ≤2.5 nM against SARS-CoV-2 PLpro. SB-140 has antiviral activity against SARS-CoV-2, MERS-CoV and SARS-CoV-1^[1].

SB-140 (15 min) potently inhibits purified SARS-CoV-2 PLpro with an IC₅₀ ≤ 2.5 nM^[1].
SB-140 (1 μM) exhibits high selectivity, with no inhibitory activity detected against 47 human DUBs and 9 cysteine proteases at a concentration of 1 μM^[1].
SB-140 (0-10 μM; 1 h) potently inhibits SARS-CoV-2 replication in A549-ACE2 cells, with an EC₅₀ of 0.3 nM and an EC₉₀ of 3 nM^[1].
SB-140 (0.01-100 μM) exhibits attenuated inhibitory activity against MERS-CoV replication in A549-ACE2 cells, with an EC₅₀ of 1.17 μM^[1].
SB-140 (0-1 μM) inhibits SARS-CoV-1 in A549-ACE2 cells, with an EC₅₀ of 14.1 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SB-140 (10 mg/kg; i.p.; twice daily; 5 days) reduces lung viral load by 15-fold in K18-hACE2 mice infected with SARS-CoV-2 variant β^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

532.60

C₂₈H₃₅F₃N₄O₃

CCOC1=CC2=C(C=CC=C2[C@@H](C)N3CCC([C@@H](CN)C(NCC(NCC#CC(F)(F)F)=O)=O)CC3)C=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sharafi M, et al. Structure-Guided Design of Potent and Selective Covalent Inhibitors Targeting the SARS-CoV-2 Papain-like Protease. J Med Chem. 2026;69(3):2197-2214.  [Content Brief]